Biogen Past Earnings Performance
Past criteria checks 0/6
Biogen's earnings have been declining at an average annual rate of -30.2%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 9.8% per year. Biogen's return on equity is 7.3%, and it has net margins of 12%.
Key information
-30.2%
Earnings growth rate
-23.6%
EPS growth rate
| Biotechs Industry Growth | 18.9% |
| Revenue growth rate | -9.8% |
| Return on equity | 7.3% |
| Net Margin | 12.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Biogen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 9,672 | 1,159 | 2,489 | 2,258 |
| 31 Mar 24 | 9,663 | 1,167 | 2,476 | 2,333 |
| 31 Dec 23 | 9,836 | 1,161 | 2,502 | 2,458 |
| 30 Sep 23 | 9,993 | 1,462 | 2,537 | 2,490 |
| 30 Jun 23 | 9,972 | 2,665 | 2,343 | 2,303 |
| 31 Mar 23 | 10,105 | 3,131 | 2,379 | 2,248 |
| 31 Dec 22 | 10,173 | 3,047 | 2,409 | 2,229 |
| 30 Sep 22 | 10,363 | 2,865 | 2,570 | 2,325 |
| 30 Jun 22 | 10,634 | 2,059 | 2,661 | 2,478 |
| 31 Mar 22 | 10,820 | 1,450 | 2,726 | 2,535 |
| 31 Dec 21 | 10,982 | 1,556 | 2,680 | 2,497 |
| 30 Sep 21 | 11,101 | 1,546 | 2,700 | 3,522 |
| 30 Jun 21 | 11,698 | 1,918 | 2,619 | 3,960 |
| 31 Mar 21 | 12,604 | 3,012 | 2,536 | 4,023 |
| 31 Dec 20 | 13,445 | 4,001 | 2,516 | 3,985 |
| 30 Sep 20 | 14,263 | 5,082 | 2,370 | 2,949 |
| 30 Jun 20 | 14,487 | 5,927 | 2,351 | 2,348 |
| 31 Mar 20 | 14,422 | 5,879 | 2,365 | 2,178 |
| 31 Dec 19 | 14,378 | 5,889 | 2,359 | 2,273 |
| 30 Sep 19 | 14,233 | 5,396 | 2,285 | 2,193 |
| 30 Jun 19 | 14,072 | 5,294 | 2,229 | 2,160 |
| 31 Mar 19 | 13,812 | 4,667 | 2,176 | 2,664 |
| 31 Dec 18 | 13,453 | 4,431 | 2,109 | 2,597 |
| 30 Sep 18 | 13,234 | 3,187 | 2,070 | 2,573 |
| 30 Jun 18 | 12,872 | 2,968 | 2,007 | 2,512 |
| 31 Mar 18 | 12,594 | 2,964 | 1,921 | 2,327 |
| 31 Dec 17 | 12,274 | 2,539 | 1,936 | 2,254 |
| 30 Sep 17 | 11,839 | 3,486 | 1,859 | 2,200 |
| 30 Jun 17 | 11,717 | 3,293 | 1,887 | 2,283 |
| 31 Mar 17 | 11,533 | 3,480 | 1,949 | 1,959 |
| 31 Dec 16 | 11,449 | 3,703 | 1,950 | 1,973 |
| 30 Sep 16 | 11,416 | 3,885 | 2,035 | 1,981 |
| 30 Jun 16 | 11,238 | 3,818 | 2,051 | 1,972 |
| 31 Mar 16 | 10,936 | 3,695 | 2,050 | 1,990 |
| 31 Dec 15 | 10,764 | 3,547 | 2,113 | 2,013 |
| 30 Sep 15 | 10,565 | 3,599 | 2,104 | 1,971 |
| 30 Jun 15 | 10,299 | 3,490 | 2,196 | 1,869 |
| 31 Mar 15 | 10,128 | 3,277 | 2,281 | 1,825 |
| 31 Dec 14 | 9,703 | 2,935 | 2,232 | 1,893 |
| 30 Sep 14 | 9,028 | 2,509 | 2,154 | 1,816 |
| 30 Jun 14 | 8,345 | 2,139 | 1,990 | 1,808 |
| 31 Mar 14 | 7,647 | 1,916 | 1,844 | 1,689 |
| 31 Dec 13 | 6,932 | 1,862 | 1,712 | 1,444 |
| 30 Sep 13 | 6,384 | 1,697 | 1,565 | 1,367 |
Quality Earnings: BIIB has a large one-off loss of $679.4M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: BIIB's current net profit margins (12%) are lower than last year (26.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIIB's earnings have declined by 30.2% per year over the past 5 years.
Accelerating Growth: BIIB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BIIB had negative earnings growth (-56.5%) over the past year, making it difficult to compare to the Biotechs industry average (-0.08%).
Return on Equity
High ROE: BIIB's Return on Equity (7.3%) is considered low.